Scholarlink

Background <p>Atorvastatin is widely prescribed for hyperlipidemia and is generally well tolerated. Auditory adverse effects are rarely reported, and statin-associated sensorineural hearing loss (SNHL) remains poorly characterized.</p> Case presentation <p>A 45-year-old Ethiopian woman developed bilateral tinnitus followed by progressive, symmetric bilateral SNHL 3&#xa0;weeks after starting atorvastatin 40&#xa0;mg daily. She had no other ototoxic risk factors. Pure-tone audiometry confirmed bilateral moderate SNHL. Given the temporal association and exclusion of alternatives, atorvastatin was discontinued. One week later, audiometry showed improvement to mild hearing loss, and at a 1-month follow-up, thresholds normalized with complete symptom resolution. She was subsequently switched to rosuvastatin 20&#xa0;mg daily, with no recurrence at a 6-month follow-up.</p> Conclusion <p>This case demonstrates that atorvastatin-associated SNHL can be reversible when recognized early. Prompt identification of new auditory symptoms and timely discontinuation of the offending medication may prevent permanent hearing impairment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Reversible bilateral sensorineural hearing loss associated with atorvastatin: a case report

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月2日

查看全文
  • Mohammedsefa Arusi Dari,
  • Zelalem Tadesse Wondimu,
  • Sara Abdulkadir Memhur,
  • Nahom Chernet Assefa

摘要

Background

Atorvastatin is widely prescribed for hyperlipidemia and is generally well tolerated. Auditory adverse effects are rarely reported, and statin-associated sensorineural hearing loss (SNHL) remains poorly characterized.

Case presentation

A 45-year-old Ethiopian woman developed bilateral tinnitus followed by progressive, symmetric bilateral SNHL 3 weeks after starting atorvastatin 40 mg daily. She had no other ototoxic risk factors. Pure-tone audiometry confirmed bilateral moderate SNHL. Given the temporal association and exclusion of alternatives, atorvastatin was discontinued. One week later, audiometry showed improvement to mild hearing loss, and at a 1-month follow-up, thresholds normalized with complete symptom resolution. She was subsequently switched to rosuvastatin 20 mg daily, with no recurrence at a 6-month follow-up.

Conclusion

This case demonstrates that atorvastatin-associated SNHL can be reversible when recognized early. Prompt identification of new auditory symptoms and timely discontinuation of the offending medication may prevent permanent hearing impairment.